Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

Rudolf Stadler; Pablo Ortiz Romero; Martine Bagot; Pietro Quaglino; Emmanuella Guenova; Constanze Jonak; Evangelina Papadavid; René Stranzenbach; Delphine Sartori; Jammbe Z Musoro; Claudette Falato; Sandrine Marreaud; Julia Jane Scarisbrick; Robert Knobler

doi:10.1016/S0959-8049(21)00668-7

Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

Rudolf Stadler
, Pablo Ortiz Romero
, Martine Bagot
, Pietro Quaglino
, Emmanuella Guenova
, Constanze Jonak
, Evangelina Papadavid
, René Stranzenbach
, Delphine Sartori
, Jammbe Z Musoro
, Claudette Falato
, Sandrine Marreaud
, Julia Jane Scarisbrick
, Robert Knobler

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S22-S23
Journal	European Journal of Cancer
Volume	156 Suppl 1
DOIs	https://doi.org/10.1016/S0959-8049(21)00668-7
Publication status	Published - Oct 2021
Externally published	Yes

Fields of science

302 Clinical Medicine

Access to Document

10.1016/S0959-8049(21)00668-7

Cite this

Stadler, R., Romero, P. O., Bagot, M., Quaglino, P., Guenova, E., Jonak, C., Papadavid, E., Stranzenbach, R., Sartori, D., Musoro, J. Z., Falato, C., Marreaud, S., Scarisbrick, J. J., & Knobler, R. (2021). Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). European Journal of Cancer, 156 Suppl 1, S22-S23. https://doi.org/10.1016/S0959-8049(21)00668-7

@article{9eef53a85cfd42499edf4a8dd04d9979,

title = "Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/S{\'e}zary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)",

author = "Rudolf Stadler and Romero, \{Pablo Ortiz\} and Martine Bagot and Pietro Quaglino and Emmanuella Guenova and Constanze Jonak and Evangelina Papadavid and Ren{\'e} Stranzenbach and Delphine Sartori and Musoro, \{Jammbe Z\} and Claudette Falato and Sandrine Marreaud and Scarisbrick, \{Julia Jane\} and Robert Knobler",

year = "2021",

month = oct,

doi = "10.1016/S0959-8049(21)00668-7",

language = "English",

volume = "156 Suppl 1",

pages = "S22--S23",

journal = "European Journal of Cancer",

issn = "1879-0852",

publisher = "Elsevier",

}

Stadler, R, Romero, PO, Bagot, M, Quaglino, P, Guenova, E, Jonak, C, Papadavid, E, Stranzenbach, R, Sartori, D, Musoro, JZ, Falato, C, Marreaud, S, Scarisbrick, JJ & Knobler, R 2021, 'Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)', European Journal of Cancer, vol. 156 Suppl 1, pp. S22-S23. https://doi.org/10.1016/S0959-8049(21)00668-7

Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). / Stadler, Rudolf; Romero, Pablo Ortiz; Bagot, Martine et al.
In: European Journal of Cancer, Vol. 156 Suppl 1, 10.2021, p. S22-S23.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

AU - Stadler, Rudolf

AU - Romero, Pablo Ortiz

AU - Bagot, Martine

AU - Quaglino, Pietro

AU - Guenova, Emmanuella

AU - Jonak, Constanze

AU - Papadavid, Evangelina

AU - Stranzenbach, René

AU - Sartori, Delphine

AU - Musoro, Jammbe Z

AU - Falato, Claudette

AU - Marreaud, Sandrine

AU - Scarisbrick, Julia Jane

AU - Knobler, Robert

PY - 2021/10

Y1 - 2021/10

UR - https://www.scopus.com/pages/publications/85116568770

U2 - 10.1016/S0959-8049(21)00668-7

DO - 10.1016/S0959-8049(21)00668-7

M3 - Article

C2 - 34649647

SN - 1879-0852

VL - 156 Suppl 1

SP - S22-S23

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

Fields of science

Access to Document

Other files and links

Cite this